Evidence map›Paper›PMID 40779358›Full record

ArticleMolecular oncology2026

Adenosine-to-inosine editing of miR-200b-3p is associated with the progression of high-grade serous ovarian cancer.

Magdalena Niemira, Anna Skwarska, Karolina Chwialkowska, Agnieszka Ostrowska, Gabriela Sokolowska, Anna Zeller, Anna Erol, Andrzej Eljaszewicz, Bartosz Hanczaruk, Anna Michalska-Falkowska and 5 more

Abstract read
In one paragraph

Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Magdalena NiemiraClinical Research Centre, Medical University of Bialystok, Poland.ORCID https://orcid.org/0000-0002-0701-4961
Anna SkwarskaComprehensive Cancer Center, Albert Einstein College of Medicine, Bronx, New York, USA.
Karolina ChwialkowskaClinical Research Centre, Medical University of Bialystok, Poland.
Agnieszka OstrowskaClinical Research Centre, Medical University of Bialystok, Poland.
Gabriela SokolowskaClinical Research Centre, Medical University of Bialystok, Poland.
Anna ZellerClinical Research Centre, Medical University of Bialystok, Poland.
Anna ErolClinical Research Centre, Medical University of Bialystok, Poland.
Andrzej EljaszewiczCentre of Regenerative Medicine, Medical University of Bialystok, Poland.
Bartosz HanczarukCentre of Regenerative Medicine, Medical University of Bialystok, Poland.
Anna Michalska-FalkowskaBiobank, Medical University of Bialystok, Poland.
Agnieszka TarasikBiobank, Medical University of Bialystok, Poland.
Joanna Reszec-GielazynBiobank, Medical University of Bialystok, Poland.
Pawel KnappUniversity Oncology Centre, University Clinical Hospital in Bialystok, Poland.
Marcin MoniuszkoCentre of Regenerative Medicine, Medical University of Bialystok, Poland.
Adam KretowskiClinical Research Centre, Medical University of Bialystok, Poland.

Funding

Ministry of Education and Science of Poland Excellence Initiative-Research UniversityNarodowe Centrum Badań i Rozwoju STRATEGMED2/266484/2/NCBR/2015
6 · The paper itself

Abstract

Deamination of adenosine to inosine (A-to-I) in double-stranded microRNAs (miRNAs) has been demonstrated to affect their function as suppressors or oncogenes in various cancers. Nevertheless, the functional impact of miRNA editing in high-grade serous ovarian cancer (HGSOC) remains largely unexplored. Here, we identified A-to-I editing in miRNAs in 60 HGSOC tissues and 48 ovarian tissues received in nononcological procedures using small RNA sequencing (RNA-Seq). To investigate the functional impact of A-to-I modifications, we tested the effect of edited RNA mimics and small interfering RNA (siRNA)-mediated downregulation of the RNA-editing enzyme double-stranded RNA-specific editase Adar (ADAR1) on cell proliferation, migration and three-dimensional (3D) growth of HGSOC cells in vitro. Tumour suppressor miR-200b-3p was the most overedited miRNA in HGSOC tumours, and the increased editing level was associated with statistically significant worse overall survival (OS). Mechanistically, in contrast to wild-type miRNA, edited miR-200b-3p promoted cell proliferation, migration and formation of 3D spheroids. Loss of function of ADAR1 profoundly repressed proliferation, migration and 3D growth of HGSOC cells. RNA-Seq and Gene Set Enrichment Analysis (GSEA) analysis revealed that, whereas wild-type miR-200b-3p induced the apoptosis pathway, edited miR-200b-3p substantially inhibited cell-cycle-related pathways. Bioinformatic prediction revealed that edited miR-200b-3p gained the function to repress the expression of new targets, including tumour suppressor MAX interactor 1, dimerisation protein (MXI1), which was associated with a statistically significantly worse OS time in HGSOC patients. Our study reports the potential contribution of edited miR-200b-3p in HGSOC progression, and highlights its potential as a new therapeutic target.

Indexed as

ADARA‐to‐I RNA editinghigh‐grade serous ovarian cancermicroRNAs

Identifiers

PMID40779358
PMCPMC12936423

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.